Device-Biotech Culture Clash: BIO Learns From Medtronic/Genzyme Deal
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's initial experience from its joint venture with Genzyme suggests that in teaming with a biotech company, the device firm must alter its view of acceptable risks and potential rewards
You may also be interested in...
Medtronic Gets To Heart Of Cell Therapy Through Genzyme Collaboration
Medtronic will draw on expertise from its three cardiac-related divisions to aid Genzyme in the development of a catheter-delivered cell therapy for cardiovascular disease
Medtronic Biotech Presence: “Pawn Or Rook?” Is VP Oesterle’s Challenge
Biologics delivery to aid organ restoration is a frontier that will permit Medtronic to advance beyond its core strengths in electromechanical implants, according to Senior VP-Medicine & Technology Stephen Oesterle
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.